Pulmonary Arterial Hypertension News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Pulmonary Arterial Hypertension - Epidemiology Forecast to 2025 - PR Newswire (press release)



Pulmonary Arterial Hypertension - Epidemiology Forecast to 2025 
PR Newswire (press release)
NEW YORK, Nov. 17, 2017 /PRNewswire/ -- DelveInsight's "Pulmonary Arterial Hypertension -Epidemiology Forecast, 2025" provides an overview of the epidemiology trends of Pulmonary Arterial Hypertension in seven major markets (US, France, Germany, ...

and more » 


Acceleron Announces Preclinical Results in Pulmonary Arterial Hypertension at the American Heart Association 2017 ... - Business Wire (press release)



BZ Weekly
 
Acceleron Announces Preclinical Results in Pulmonary Arterial Hypertension at the American Heart Association 2017 ... 
Business Wire (press release)
?We are extremely encouraged by these positive preclinical results, which support our mechanistic approach for sotatercept and its potential to be a first-in-class disease-modifying therapy for patients with pulmonary arterial hypertension. We look ...
SEC FORM 4 - SEC.gov SEC.gov
Stock and Industry Analysis Reports, Daily Technical Portfolio - American Consumer News, LLC American Consumer News, LLC
SEC FORM 4 - SEC.gov SEC.gov

all 77 news articles » 


Pulmonary Arterial Hypertension: Using Biomarkers to Assess Treatment Response - Pulmonology Advisor



Pulmonology Advisor
 
Pulmonary Arterial Hypertension: Using Biomarkers to Assess Treatment Response 
Pulmonology Advisor
Pulmonary arterial hypertension (PAH) affects an estimated 10 to 52 adults per million.1. Because symptoms may not become apparent until patients are in the advanced stages of the disease, detection and diagnosis are often delayed.2 Once the diagnosis ...
Preclinical Data Supports Sotatercept Being Tested in People with PAH, Acceleron Reports Pulmonary Hypertension News

all 2 news articles » 


Pulmonary Arterial Hypertension: Mechanisms of Exercise Intolerance - Pulmonology Advisor



Pulmonology Advisor
 
Pulmonary Arterial Hypertension: Mechanisms of Exercise Intolerance 
Pulmonology Advisor
Although available therapies for pulmonary arterial hypertension (PAH) have expanded in recent years, the disease continues to carry a poor prognosis, with an approximate 50% mortality rate within 7 years after diagnosis.1 In addition, the hallmark ...

 


Pulmonary Arterial Hypertension in Systemic Sclerosis: Swift Diagnosis and Effective Treatment - Rheumatology Advisor



Rheumatology Advisor
 
Pulmonary Arterial Hypertension in Systemic Sclerosis: Swift Diagnosis and Effective Treatment 
Rheumatology Advisor
SAN DIEGO ? Rheumatology specialists should be aware of the clinical features of systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH), as well as the tools available to facilitate a prompt and accurate diagnosis, according to Ruth ...
Pulmonary Arterial Hypertension - Market Insights, Epidemiology and Market Forecast - 2025 PR Newswire (press release)
Pulmonary Arterial Hypertension (PAH) - Market Insights, Epidemiology and Market Forecast - 2025 Markets Insider
New Market Research: Pulmonary Arterial Hypertension Pipeline Review H2 2017 Development by Therapy Area ... MilTech
satPRnews (press release) 
all 6 news articles » 


Assessment of Life Expectancy in Scleroderma-Associated Pulmonary Arterial Hypertension - Rheumatology Advisor



Rheumatology Advisor
 
Assessment of Life Expectancy in Scleroderma-Associated Pulmonary Arterial Hypertension 
Rheumatology Advisor
SAN DIEGO ? Patients with scleroderma-associated isolated pulmonary arterial hypertension (SSc-PAH) have a slightly higher mortality risk than patients with scleroderma-associated pulmonary hypertension with concomitant interstitial lung disease ...

 


Bayer to Present Pulmonary Arterial Hypertension Data at the 2017 ... - PR Newswire (press release)



Bayer to Present Pulmonary Arterial Hypertension Data at the 2017 ... 
PR Newswire (press release)
WHIPPANY, N.J., Oct. 24, 2017 /PRNewswire/ -- Bayer announced today that data from its pulmonary disease franchise will be presented in scientific sessions at ...

and more » 


United Therapeutics Announces Additional Six Months Of Regulatory Exclusivity For AdcircaŽ - Markets Insider



United Therapeutics Announces Additional Six Months Of Regulatory Exclusivity For AdcircaŽ 
Markets Insider
United Therapeutics markets and sells Adcirca for treatment of pulmonary arterial hypertension (PAH) in the United States under a license agreement with Lilly. A U.S. patent for Adcirca will expire November 21, 2017, and FDA's decision provides an ...

and more » 


Targeting mitochondria in pulmonary hypertension - Medical Xpress - Medical Xpress



Medical Xpress
 
Targeting mitochondria in pulmonary hypertension - Medical Xpress 
Medical Xpress
A new compound called DCA improved lung function for pulmonary arterial hypertension patients. Credit: E.D. Michelakis et al., Science Translational Medicine ...
New hope for pulmonary hypertension thanks to old drug | CTV News CTV News

all 2 news articles » 


Phaware Podcast: Steve Mathai, MD (Part 1) - Pulmonary Hypertension News



Pulmonary Hypertension News
 
Phaware Podcast: Steve Mathai, MD (Part 1) 
Pulmonary Hypertension News
But for pulmonary hypertension, we treat it more like we treat pulmonary hypertension as in patients who have idiopathic pulmonary arterial hypertension or other forms of pulmonary arterial hypertension. We tend to treat both disease states at the same ...